Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12218306 | 0.86 | NPC1 (0.53) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL14367237 | 0.80 | DEGS1 (0.64) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL12431142 | 0.76 | DEGS1 (0.59) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL15706299 | 0.76 | DEGS1 (0.82) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL14014144 | 0.75 | DEGS1 (0.76) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL2233174 | 0.75 | DEGS1 (0.76) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL30794981 | 0.74 | HDAC4 (0.57) | HTTHDAC4NPC1DEGS1ALDH1A1 | |
| SCHEMBL6339509 | 0.74 | HDAC4 (0.71) | HTTHDAC4DEGS1ALDH1A1NAMPT | |
| SCHEMBL16639029 | 0.74 | HDAC4 (0.71) | HTTHDAC4DEGS1ALDH1A1NAMPT | |
| SCHEMBL3380172 | 0.73 | POLB (0.60) | HTTHDAC4NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011085351-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| WO-2011085351-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |